hVEGF26-104 + RFASE

hVEGF26-104 + RFASE is a therapeutic cancer vaccine developed by Pepscan Systems BV. The vaccine consists of a synthetic 79-amino acid peptide mimic (hVEGF26-104), which corresponds to amino acids 26-104 of the human VEGF165 isoform, formulated with the sulpholipopolysaccharide adjuvant RFASE (Raffinose Fatty Acid Sulphate Ester) in an oil-in-water emulsion. It is designed to target vascular endothelial growth factor-A (VEGF-A) to induce an immune response that generates neutralizing anti-VEGF antibodies, thereby inhibiting tumor angiogenesis. The vaccine was evaluated in a Phase I clinical trial (NCT02237638) for patients with advanced solid malignancies. Although it demonstrated a favorable safety profile, it failed to induce seroconversion against native VEGF165 in humans, leading to a pending development status.

Other names

hVEGF26-104/RFASEVEGF-A peptide vaccine